MA71557A - Composants d'édition génique, systèmes et procédés d'utilisation - Google Patents

Composants d'édition génique, systèmes et procédés d'utilisation

Info

Publication number
MA71557A
MA71557A MA71557A MA71557A MA71557A MA 71557 A MA71557 A MA 71557A MA 71557 A MA71557 A MA 71557A MA 71557 A MA71557 A MA 71557A MA 71557 A MA71557 A MA 71557A
Authority
MA
Morocco
Prior art keywords
systems
methods
gene editing
editing components
components
Prior art date
Application number
MA71557A
Other languages
English (en)
French (fr)
Inventor
Vladimir PRESNYAK
Muthusamy Jayaraman
Elisabeth NARAYANAN
Giedrius GASIUNAS
Alim Ladha
Original Assignee
Renagade Therapeutics Management Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/297,346 external-priority patent/US20240084274A1/en
Application filed by Renagade Therapeutics Management Inc. filed Critical Renagade Therapeutics Management Inc.
Publication of MA71557A publication Critical patent/MA71557A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA71557A 2022-07-18 2023-07-17 Composants d'édition génique, systèmes et procédés d'utilisation MA71557A (fr)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US202263368728P 2022-07-18 2022-07-18
US202263368731P 2022-07-18 2022-07-18
US202263368736P 2022-07-18 2022-07-18
US202263368744P 2022-07-18 2022-07-18
US202263368742P 2022-07-18 2022-07-18
US202263368722P 2022-07-18 2022-07-18
US202263368730P 2022-07-18 2022-07-18
US202263368734P 2022-07-18 2022-07-18
US202263368738P 2022-07-18 2022-07-18
US202263368741P 2022-07-18 2022-07-18
US202263368726P 2022-07-18 2022-07-18
US202263368737P 2022-07-18 2022-07-18
US202263368735P 2022-07-18 2022-07-18
US202263368724P 2022-07-18 2022-07-18
US18/297,346 US20240084274A1 (en) 2022-07-18 2023-04-07 Gene editing components, systems, and methods of use
US202363495198P 2023-04-10 2023-04-10
EP23754608.0A EP4558624A2 (de) 2022-07-18 2023-07-17 Geneditierkomponenten, systeme und verfahren zur verwendung
PCT/US2023/070339 WO2024020346A2 (en) 2022-07-18 2023-07-17 Gene editing components, systems, and methods of use

Publications (1)

Publication Number Publication Date
MA71557A true MA71557A (fr) 2025-05-30

Family

ID=89618555

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71557A MA71557A (fr) 2022-07-18 2023-07-17 Composants d'édition génique, systèmes et procédés d'utilisation

Country Status (8)

Country Link
EP (1) EP4558624A2 (de)
JP (1) JP2025525569A (de)
CN (1) CN120344660A (de)
AU (1) AU2023311964A1 (de)
CA (1) CA3262406A1 (de)
MA (1) MA71557A (de)
TW (1) TW202421205A (de)
WO (1) WO2024020346A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023056291A1 (en) 2021-09-28 2023-04-06 Acrigen Biosciences Compositions and methods for nucleic acid modifications
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
AU2024234874A1 (en) 2023-03-15 2025-10-09 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025210147A1 (en) * 2024-04-04 2025-10-09 Alia Therapeutics Srl Type v cas proteins and applications thereof
US12480141B2 (en) 2024-04-04 2025-11-25 Alia Therapeutics Srl Type V Cas proteins and applications thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5135855A (en) 1986-09-03 1992-08-04 The United States Of America As Represented By The Department Of Health And Human Services Rapid, versatile and simple system for expressing genes in eukaryotic cells
EP0273085A1 (de) 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
US5591601A (en) 1993-05-14 1997-01-07 Ohio University Edison Animal Biotechnology Institute DNA polymerase gene expression system utilizing an RNA polymerase co-delivered with the gene expression vector system
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
EP0831854A4 (de) 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc Oligonukleotide mit phosphorothioat-bindungen von hoher chiraler reinheit
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
DK1175497T3 (da) 1999-04-14 2010-05-31 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
EP1235914A2 (de) 1999-11-24 2002-09-04 Joseph Rosenecker Polypeptide, die multimere von kern-signallokalisierungs- oder proteintransfer- domänen enthalten und ihre verwendung zum transfer biologischer moleküle in zellen
AU2281201A (en) 1999-12-29 2001-07-09 A. James Mixson Histidine copolymer and methods for using same
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
WO2001081609A2 (en) 2000-03-22 2001-11-01 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US20030021766A1 (en) 2001-01-12 2003-01-30 Michael Vajdy Nucleic acid mucosal immunization
JP4608210B2 (ja) 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
PT1857122E (pt) 2001-06-05 2011-03-07 Curevac Gmbh Arnm estabilizado com teor de g/c aumentado, codificando para um antigénio viral
US20050183161A1 (en) 2003-10-14 2005-08-18 Athenix Corporation AXMI-010, a delta-endotoxin gene and methods for its use
WO2005066202A2 (en) 2003-12-22 2005-07-21 E.I. Du Pont De Nemours And Company Bacillus cry9 family members
WO2006060182A2 (en) 2004-11-17 2006-06-08 University Of Maryland, Baltimore HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
EP2342336B1 (de) 2008-09-05 2016-12-14 President and Fellows of Harvard College Kontinuierliche gerichtete evolution von proteinen und nukleinsäuren
EP2449109B1 (de) 2009-07-02 2016-09-28 Athenix Corporation Axmi-205-pestizidgen und anwendungsverfahren dafür
EP2525781A1 (de) 2010-01-22 2012-11-28 Schering Corporation Neue kationische lipide zur abgabe von oligonukleotiden
WO2011136368A1 (ja) 2010-04-28 2011-11-03 協和発酵キリン株式会社 カチオン性脂質
US8802934B2 (en) 2010-08-19 2014-08-12 Pioneer Hi Bred International Inc Bacillus thuringiensis gene with lepidopteran activity
CA2825370A1 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
HK1200089A1 (en) 2011-12-07 2015-07-31 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
CA2856737C (en) 2011-12-07 2023-09-26 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
SI3401400T1 (sl) 2012-05-25 2019-10-30 Univ California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
CN105188767A (zh) 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3064585B1 (de) 2012-12-12 2020-02-05 The Broad Institute, Inc. Technische bearbeitung und optimierung von verbesserten systemen, verfahren und enzymzusammensetzungen zur sequenzenmanipulation
ES2536353T3 (es) 2012-12-12 2015-05-22 The Broad Institute, Inc. Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
EP2931898B1 (de) 2012-12-12 2016-03-09 The Broad Institute, Inc. Technische konzeption und optimierung von systemen, verfahren und zusammensetzungen zur sequenzmanipulation funktionellen domänen
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
BR112015013784A2 (pt) 2012-12-12 2017-07-11 Massachusetts Inst Technology aplicação, manipulação e otimização de sistemas, métodos e composições para manipulação de sequência e aplicações terapêuticas
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
CN105074061B (zh) 2012-12-13 2021-03-09 美国陶氏益农公司 位点特异性核酸酶活性的dna检测方法
DK3553174T3 (da) 2012-12-17 2025-08-04 Harvard College Rna-guided modificering af humant genom
EP2958996B1 (de) 2013-02-25 2019-10-16 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur verbesserung einer nuklease-vermittelten genunterbrechung
US20140315985A1 (en) 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
WO2014144155A1 (en) 2013-03-15 2014-09-18 Regents Of The University Of Minnesota Engineering plant genomes using crispr/cas systems
US9885033B2 (en) 2013-03-15 2018-02-06 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US20140364333A1 (en) 2013-03-15 2014-12-11 President And Fellows Of Harvard College Methods for Live Imaging of Cells
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
UA121197C2 (uk) 2013-04-05 2020-04-27 Доу Агросайенсіс Ллс Нуклеаза "цинкові пальці" для модифікацїї гена ahas та спосіб її використання
SG10201808935WA (en) 2013-04-16 2018-11-29 Regeneron Pharma Targeted modification of rat genome
JP2016518142A (ja) 2013-05-10 2016-06-23 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
EP2999788B1 (de) 2013-05-22 2020-07-08 Northwestern University Rna-gerichtete dna-spaltung und genmanipulation durch das enzym cas9 aus neisseria meningitidis
US11414695B2 (en) 2013-05-29 2022-08-16 Agilent Technologies, Inc. Nucleic acid enrichment using Cas9
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3190963A4 (de) 2014-09-11 2018-04-25 The Medical College of Wisconsin, Inc. Systeme und verfahren zur beurteilung von histologischen merkmalen von medizinischen bildern mittels eines trainierten modells
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
JP7030522B2 (ja) 2015-05-11 2022-03-07 エディタス・メディシン、インコーポレイテッド 幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
CA2998810A1 (en) 2015-09-17 2017-03-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
RS63986B1 (sr) 2015-10-28 2023-03-31 Acuitas Therapeutics Inc Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
US20210206818A1 (en) 2016-01-22 2021-07-08 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
CA3034681A1 (en) 2016-06-30 2018-01-04 Arbutus Biopharma Corporation Compositions and methods for delivering messenger rna
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
JP7355731B2 (ja) 2017-08-16 2023-10-03 アクイタス セラピューティクス インコーポレイテッド 脂質ナノ粒子製剤における使用のための脂質
WO2019135816A2 (en) 2017-10-23 2019-07-11 The Broad Institute, Inc. Novel nucleic acid modifiers
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP3746052A1 (de) 2018-01-30 2020-12-09 Modernatx, Inc. Zusammensetzungen und verfahren zur abgabe von wirkstoffen an immunzellen
MA52766A (fr) 2018-05-30 2021-04-14 Translate Bio Inc Lipides cationiques vitaminiques
EP3844272A1 (de) 2018-08-28 2021-07-07 Flagship Pioneering Innovations VI, LLC Verfahren und zusammensetzungen zum modulieren eines genoms
WO2020139783A2 (en) 2018-12-27 2020-07-02 Lifeedit, Inc. Polypeptides useful for gene editing and methods of use
WO2020142754A2 (en) * 2019-01-04 2020-07-09 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
EP3942042A1 (de) 2019-03-19 2022-01-26 The Broad Institute, Inc. Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
WO2021016075A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CA3155075A1 (en) 2019-10-18 2021-04-22 Michael Mitchell Lipid nanoparticles and formulations thereof for car mrna delivery
MX2022005328A (es) * 2019-11-05 2022-07-21 Pairwise Plants Services Inc Composiciones y metodos para el reemplazo de alelos con adn codificado por arn.
EP4085141A4 (de) 2019-12-30 2024-03-06 The Broad Institute, Inc. Genomeditierung unter verwendung von reverser transkriptase für vollständig aktive crispr-komplexe
JP7605852B2 (ja) * 2020-03-06 2024-12-24 メタゲノミ，インク． クラスｉｉのｖ型ｃｒｉｓｐｒ系
WO2021178934A1 (en) * 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
MX2022011562A (es) 2020-03-19 2022-12-13 Intellia Therapeutics Inc Métodos y composiciones para edición dirigida de genoma.
CN113874507A (zh) 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
CN114391008B (zh) 2020-08-20 2024-05-03 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
EP4214314A4 (de) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr-editierung zum einbetten von nukleinsäurelandepads in genome von lebenden zellen
AU2021364781B2 (en) 2020-10-21 2025-10-09 Massachusetts Institute Of Technology Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
CA3220689A1 (en) 2021-05-28 2022-12-01 Ciaran LAWLOR Lipid nanoparticles and methods of use thereof
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
EP4402121A1 (de) 2021-09-14 2024-07-24 Renagade Therapeutics Management Inc. Acyclische lipide und verfahren zur verwendung davon
WO2023056291A1 (en) * 2021-09-28 2023-04-06 Acrigen Biosciences Compositions and methods for nucleic acid modifications

Also Published As

Publication number Publication date
CN120344660A (zh) 2025-07-18
WO2024020346A2 (en) 2024-01-25
CA3262406A1 (en) 2024-01-25
TW202421205A (zh) 2024-06-01
AU2023311964A1 (en) 2025-01-30
JP2025525569A (ja) 2025-08-05
EP4558624A2 (de) 2025-05-28
WO2024020346A3 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
MA71557A (fr) Composants d'édition génique, systèmes et procédés d'utilisation
EP3908201A4 (de) Systeme und verfahren zur medizinischen klammerung
EP3949467A4 (de) Systeme und verfahren zur notfalldatenintegration
EP3841486A4 (de) Systeme und verfahren für blockchain-verknüpfung und beziehungen
EP3934519A4 (de) Systeme und verfahren zur chirurgischen registrierung
EP3946329A4 (de) Beta-adrenerger agonist und verfahren zu seiner verwendung
EP4298785A4 (de) Systeme und verfahren für virtuelle interaktion
EP3986230A4 (de) Absorbierende auskleidung, systeme und verwendungsverfahren
EP4031289A4 (de) Klebstoffsplittersysteme und verfahren zur verwendung davon
EP3930589A4 (de) Klammermagazinanordnungen und zugehörige vorrichtungen, systeme und verfahren
EP3830012A4 (de) Automatisierte gatteranordnungen und systeme sowie verfahren zu ihrer herstellung und verwendung
EP3962481A4 (de) Kcnt1-hemmer und verfahren zur verwendung
EP3791570A4 (de) Systeme und verfahren zur kreuzredigierung
EP4048402A4 (de) Modifizierte zytotoxische t-zellen und verfahren zur verwendung davon
EP4133054A4 (de) Skalierbare bioreaktorsysteme und zugehörige verfahren zur verwendung
EP3935622A4 (de) Systeme und verfahren zum umsetzen von gesprochener oder textueller eingabe in musik
MA55381A (fr) Pyridazinones et leurs procédés d'utilisation
EP4031214A4 (de) Einspritzsysteme und verfahren zu deren verwendung
EP3765006A4 (de) Arginasehemmer und verfahren zur verwendung
EP4100827A4 (de) Eingriffssysteme und verfahren für roboterkommissioniersysteme
EP4315183A4 (de) Systeme und verfahren zur aufgabenbestimmung, -delegierung und -automatisierung
EP3810615A4 (de) Arginase-inhibitoren und verfahren zur verwendung
EP4241247A4 (de) Systeme und verfahren zur integration und verwendung von technologien für erweiterte realität
EP4363673A4 (de) Kupplungssystem, kupplungswerkzeuge und verfahren zur verwendung davon
EP4126288A4 (de) Systeme und verfahren zur reinigung von lösungsmitteln